• TG003 Cdc2-like Kinase Inhibitor Workflows

  2026-08-30

  TG003 enables controlled interrogation of Clk-dependent phosphorylation, alternative splicing, and platinum-response biology in the same experimental framework. This practical guide connects splicing assays with ovarian cancer resistance models while emphasizing controls needed to distinguish CLK2 effects from broader Clk or CK1 activity.

• ATP and the Translational Logic of p21 mRNA-LNP

  2026-08-29

  Localized p21 mRNA delivery illustrates how mechanistic biology, assay design, and reagent quality must converge for translational success. This thought-leadership analysis explains where ATP Solution (100 mM) supports kinase, transcription, ligation, and phosphorylation workflows while distinguishing experimental infrastructure from therapeutic evidence.

• CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer

  2026-08-28

  The reference study identifies Cdc2-like kinase 2 (CLK2) as a molecular determinant of platinum resistance in ovarian cancer and links its activity to BRCA1 phosphorylation at Ser1423. By integrating patient-tissue profiling, cellular experiments, mechanistic analysis, and xenograft studies, the work provides a rationale for investigating CLK2-dependent DNA damage repair as a therapeutic vulnerability.

• TG003: Cdc2-like Kinase Inhibitor Workflows

  2026-08-28

  TG003 connects precise Clk-family inhibition with practical assays for alternative splicing, platinum resistance, and exon-skipping research. This guide translates kinase selectivity data and ovarian cancer findings into dosing, readout, and troubleshooting strategies while clearly separating validated evidence from exploratory applications.

• AM 281: Designing Causal CB1 Neuroassays

  2026-08-27

  AM 281 is a selective CB1 cannabinoid receptor antagonist for dissecting endocannabinoid control of glutamate homeostasis and cognition. This article presents an assay-design framework that connects receptor pharmacology, astrocytic GLT-1 regulation, and behavioral validation without confusing pathway correlation with causality.

• Chromatin Programs in Perinatal Cardiomyocyte Transition

  2026-08-27

  The reference study integrates chromatin accessibility, long-range chromatin interactions, and gene expression to define how cardiomyocytes transition from fetal to neonatal states. Its identification of MEF2- and AP-1-centered regulatory programs provides a framework for interpreting maturation and for improving the developmental state of induced pluripotent stem cell-derived cardiomyocytes.

• WSP-5 for Reliable H2S Cell Assays

  2026-08-26

  WSP-5 (SKU C3378) provides a turn-on fluorescent readout for endogenous and exogenous hydrogen sulfide, supporting live-cell imaging and cytotoxicity workflows. This scenario-based guide covers assay design, DMSO handling, controls, interpretation, and practical supplier selection.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit

  2026-08-26

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit enables customizable fluorescent RNA probe synthesis by T7 transcription. This guide explains how Cy3-UTP incorporation can be integrated with spatial and membrane-based assays while avoiding confusion between probe detection and therapeutic mRNA delivery.

• Ferrostatin-1: A Mechanistic Guide to Ferroptosis

  2026-08-25

  Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it is a critical mechanistic control for separating lipid peroxidation from upstream stress signaling. This guide uses a recent ovarian-function study to show how Fer-1 can strengthen ferroptosis assays and improve interpretation across disease models.

• ERADECs Enable ERAD-Based Membrane Protein Degradation

  2026-08-25

  Song et al. describe ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that redirects the endoplasmic reticulum-associated degradation pathway toward transmembrane proteins. PD-L1-directed ERADECs showed highly potent degradation and stronger tumor suppression than a clinically used PD-L1 antibody in vivo, while desonide-mediated engagement of SYVN1 extended the concept to mutant huntingtin.

• Dextran Microgels for Oral Colon Cancer Therapy

  2026-08-24

  The reference study develops a sequentially targeted oral system that combines dextran microgels with cisplatin/SPION lipid nanoparticles for localized colon cancer treatment. Its design links colon-selective enzymatic release, folate-receptor-mediated tumor-cell uptake, and magnetic hyperthermia to improve local efficacy while limiting premature gastrointestinal exposure.

• TG003: A Cdc2-like Kinase Inhibitor in Splicing

  2026-08-24

  TG003 is a practical Cdc2-like kinase inhibitor for connecting serine/arginine-rich protein phosphorylation with alternative splicing, exon selection, and drug-response phenotypes. This guide translates its biochemical profile into workflows for splice-site selection research, Duchenne muscular dystrophy models, and mechanistic studies of platinum-resistant ovarian cancer.

• Bay 11-7085: Translating NF-κB Mechanisms

  2026-08-23

  Bay 11-7085 is more than a pathway inhibitor: it is a practical chemical probe for testing whether NF-κB activity connects inflammatory signaling to apoptosis and tissue injury. This thought-leadership guide links its mechanism to endometriosis and pneumococcal meningitis models, while outlining validation strategies, translational limitations, and a more rigorous way to position NF-κB inhibition in research programs.

• SARS-CoV-2 N Protein Rewires GADD34 Immunity

  2026-08-22

  The reference study identifies an atypical stress-granule mechanism through which SARS-CoV-2 nucleocapsid protein suppresses GADD34 expression and weakens IRF3-dependent interferon signaling. Its central advance is linking GADD34 mRNA sequestration in N+/G3BP1+ foci to impaired innate immunity and enhanced viral replication, while also defining a KVRF motif-dependent role for GADD34 in IRF3 nuclear translocation.

• 3-Aminobenzamide (PARP-IN-1) Guide

  2026-08-22

  A scenario-based laboratory guide to using 3-Aminobenzamide (PARP-IN-1), SKU A4161, in cell viability, proliferation, cytotoxicity, oxidative-stress, and PARP activity studies. It explains concentration selection, controls, data interpretation, storage, and practical vendor-selection criteria using product data and peer-reviewed evidence.

8012 records 1/535 page Next 12345 下5页 Last page